- Home
- AG vs BMRN Comparison
AG vs BMRN Comparison
Compare AG & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AG | BMRN |
|---|---|---|
| Founded | 1979 | 1996 |
| Country | Canada | United States |
| Employees | N/A | 3221 |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2B | 10.9B |
| IPO Year | 2004 | 1999 |
Fundamental Metrics
Financial Performance| Metric | AG | BMRN |
|---|---|---|
| Price | $22.12 | $57.23 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 18 |
| Target Price | $21.92 | ★ $88.22 |
| AVG Volume (30 Days) | ★ 18.3M | 1.7M |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.11% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.80 |
| Revenue | N/A | ★ $1,313,646,000.00 |
| Revenue This Year | $13.75 | $14.30 |
| Revenue Next Year | $26.43 | $11.65 |
| P/E Ratio | $143.01 | ★ $31.35 |
| Revenue Growth | N/A | ★ 17.62 |
| 52 Week Low | $5.19 | $50.76 |
| 52 Week High | $32.00 | $68.54 |
Technical Indicators
Market Signals| Indicator | AG | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 49.57 | 50.06 |
| Support Level | $20.21 | $56.66 |
| Resistance Level | $27.90 | $59.63 |
| Average True Range (ATR) | 1.44 | 1.57 |
| MACD | 0.02 | 0.06 |
| Stochastic Oscillator | 65.61 | 52.28 |
Price Performance
Historical ComparisonAbout AG First Majestic Silver Corp. (Canada)
First Majestic Silver Corp is engaged in the production, development, exploration, and acquisition of mineral properties with a focus on silver and gold production in North America. It owns three producing mines in Mexico consisting of the San Dimas Silver/Gold Mine, the Santa Elena Silver/Gold Mine, and the La Encantada Silver Mine.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.